| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2bcaf91101a370a3d64e3190366357f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2018-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50fd9736e4f149cb1c2ee2efc189801b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afc9bd9f86ee59b2ea27cd8bd585440b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94d5fdec7d83718d00c20f19fd935df0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04ecbc089e7e30c5d942ae6ff0e123b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea114eba14e835422e308ff1d6ecb53f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a2a9d8ac35b903b59396c6ee952ec79 |
| publicationDate |
2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019016213-A1 |
| titleOfInvention |
ANTIBODIES β (Aβ) AMYLOIDS ANTI-ISOASP7 AND USES THEREOF |
| abstract |
The present invention relates to the field of medicine. The present invention particularly relates to antibodies and antigen-binding fragments thereof which can bind amyloid β-isoAsp7 (Aβ) and a pharmaceutical composition comprising antibodies or antigen-binding fragments thereof. them. Isoasp7 Aβ can be found in the plaques of Alzheimer's patients and is therefore a suitable target for the treatment and / or prevention of Aβ-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof, and the pharmaceutical composition comprising either, can be used to treat and / or prevent neurodegenerative diseases. The present invention further relates to hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and / or prognosis of a neurodegenerative disease and a method for the detection of isoAsp7 Aβ in an isolated sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11440953-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434284-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434285-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434283-B2 |
| priorityDate |
2017-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |